POST Online Media Lite Edition


U.S. launches investigation of drug prices

Staff writer |
A U.S. Senate panel launched a bipartisan probe into pharmaceutical pricing, seeking documents from four drugmakers including Valeant Pharmaceuticals and Turing Pharmaceuticals.

Article continues below

The Senate's Special Committee on Aging also requested information from Retrophin and Rodelis Therapeutics, according to a statement from the panel's Republican Chairwoman Susan Collins and Claire McCaskill, its top Democrat.

Democratic members of a U.S. House of Representatives investigative committee asked Republicans to call a vote to subpoena Valeant and Turing.

Democratic leaders began calling for investigation of drug prices in September, emboldened by press reports of a more than 5000 percent overnight increase in a toxoplasmosis drug made by Turing and a more than 600 percent increase in a blood pressure treatment from Valeant.

Drugmakers and their defenders say drugs are priced to help enable discovery and development of innovative new treatments.

What to read next

EU accusing Gazprom of abusing dominant position, fine could reach 16bn
EU's anti-dumping on biodiesel from Argentina and Indonesia
Europe opens investigation into gas export restrictions from Romania